Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. (January 2016)

• Record Type: Journal Article
• Authors: Kaplan, Jonah A.; Liu, Rong; Freedman, Jonathan D.; Padera, Robert; Schwartz, John; Colson, Yolonda L.; Grinstaff, Mark W.
• Is Part Of: Biomaterials. Volume 76(2016)
• Page Start: 273
• Page End: 281
• Publication Date: 2016-01
• Subjects: Drug delivery -- Electrospinning -- Nanofibers -- Lung cancer -- Surgery -- Superhydrophobic; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2015.10.060
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: For early stage lung cancer patients, local cancer recurrence after surgical resection is a significant concern and stems from microscopic disease left behind after surgery. Here we apply a local drug delivery strategy to combat local lung cancer recurrence after resection using non-woven, biodegradable nanofiber meshes loaded with cisplatin. The meshes are fabricated using a scalable electrospinning process from two biocompatible polymers—polycaprolactone and poly(glycerol monostearate- co -caprolactone)—to afford favorable mechanical properties for use in a dynamic tissue such as the lung. Owing to their rough nanostructure and hydrophobic polymer composition, these meshes exhibit superhydrophobicity, and it is this non-wetting nature that sustains the release of cisplatin in a linear fashion over ∼90 days, with anti-cancer efficacy demonstrated using an in vitro Lewis Lung carcinoma (LLC) cell assay. The in vivo evaluation of cisplatin-loaded superhydrophobic meshes in the prevention of local cancer recurrence in a murine model of LLC surgical resection demonstrated a statistically significant increase ( p = 0.0006) in median recurrence-free survival to >23 days, compared to standard intraperitoneal cisplatin therapy of equivalent dose. These results emphasize the importance of supplementing cytoreductive surgery with local drug delivery strategies to improve prognosis for lung cancer patients undergoing tumor resection.